Publicaciones en colaboración con investigadores/as de Seoul National University Hospital (19)

2024

  1. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

2021

  1. Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0)

    BMC Nephrology

  2. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

    BMC Nephrology, Vol. 22, Núm. 1

2020

  1. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1

  2. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

  3. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

2019

  1. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment

    Journal of the American College of Cardiology, Vol. 73, Núm. 4, pp. 444-453

2018

  1. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  2. Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 15, pp. 1437-1449

  3. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2017

  1. Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study

    International Journal of Cardiology, Vol. 243, pp. 15-20

  2. Fractional Flow Reserve/Instantaneous Wave-Free Ratio Discordance in Angiographically Intermediate Coronary Stenoses: An Analysis Using Doppler-Derived Coronary Flow Measurements

    JACC: Cardiovascular Interventions, Vol. 10, Núm. 24, pp. 2514-2524

  3. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI

    New England Journal of Medicine, Vol. 376, Núm. 19, pp. 1824-1834

2016

  1. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial

    The Lancet Oncology, Vol. 17, Núm. 5, pp. 577-589

2015

  1. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

    British Journal of Cancer, Vol. 113, Núm. 1, pp. 12-19

  2. Usefulness of combined intravascular ultrasound parameters to predict functional significance of coronary artery stenosis and determinants of mismatch

    EuroIntervention, Vol. 11, Núm. 2, pp. 163-170

2014

  1. Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: The RESOLVE study

    Journal of the American College of Cardiology, Vol. 63, Núm. 13, pp. 1253-1261

2013

  1. Hybrid iFR-FFR decision-making strategy: Implications for enhancing universal adoption of physiology-guided coronary revascularisation

    EuroIntervention, Vol. 8, Núm. 10, pp. 1157-1165

2012

  1. Functional guidance with FFR: An effective and safe way to simplify percutaneous treatment of coronary bifurcations

    EuroIntervention